AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

In September, AstraZeneca's subsidiary MedImmune gained approval for a live H1N1 Flumist vaccine. Further afield, Beijing-based Sinovac Biotech also received approval for an H1N1 vaccine from the ...

If you’re on the fence about investing in AstraZeneca plc (ADR) or Merck & Co Inc because ... Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses.

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 billion. However many analysts felt the company had paid far too much ...

See your plan by selecting location, age, and other applicable factors Sign up to be alerted when there are vaccination updates in your state: The Plan Your Vaccine page will be updated as new ...

Oct. 23, 2024 — Maternal antibodies passed across the placenta can interfere with the response to the malaria vaccine, which would explain its lower efficacy in infants under five months of age ...